Singapore’s GIC looks for lab rat liquidity

An employee carries test tubes inside a laboratory at Piramal's Research Centre in Mumbai August 11, 2014. REUTERS/Danish Siddiqui

NEW YORK, July 27 (Reuters Breakingviews) - It has been a great year to sell firms that run clinical trials for drugmakers. Now Singapore’s sovereign wealth fund GIC is seeking some lab rat liquidity, too. It’s floating WCG Clinical in an initial public offering that could give the firm a toppy market capitalization of more than $6 billion.

Long- and short-run trends are both favorable for these businesses. Biotechnology firms are outsourcing more drug development work, and trials are becoming bigger and more complex. The result is steady revenue growth over the long run. And this year will be even better as pandemic-delayed work comes home. WCG’s first-quarter revenue grew by a third compared to last year.

But valuations are starting to presuppose success. At the top of the range, WCG’s enterprise value would be over $7 billion. That’s 32 times its adjusted EBITDA for last year. In February, Dublin-based ICON bought PRA Health for $12 billion, or about 24 times historic adjusted EBITDA, and its stock fell 8% on that news as investors reckoned it overpaid. (By Robert Cyran)

On Twitter

Capital Calls - More concise insights on global finance:

FirstGroup’s CEO exit sets course for rocky ride read more

Just Eat Takeaway’s activist has a full plate read more

Duolingo IPO valuation doesn’t translate read more

SoftBank tries to turn dog into unicorn read more

Mediobanca reaches for low-hanging wealth fruit read more

Editing by Lauren Silva Laughlin and Amanda Gomez

Our Standards: The Thomson Reuters Trust Principles.

Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.